NCT00718380 2017-11-21
A Phase 1 Study of ABT-869 in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
Clinical Trials
14 trialsNCT00733187 2017-11-21
Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869
AbbVie
Phase 1 Completed
NCT01225302 2017-11-21
A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 1 Completed
NCT01413893 2017-11-21
An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
AbbVie
Phase 1 Completed
NCT00716534 2013-04-29
Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 2 Completed
NCT00517790 2013-04-05
Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
AbbVie
Phase 2 Completed
NCT00645177 2013-01-29
Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer
AbbVie
Phase 2 Completed
NCT01286974 2012-09-21
A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
Abbott
Phase 1 Terminated
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated
NCT01506934 2012-08-28
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
Abbott
Phase 1 Terminated
NCT01381341 2012-03-23
To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.
Abbott
Phase 1 Completed
NCT01401933 2011-11-02
Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
Abbott
Phase 1 Completed
NCT01114191 2011-07-26
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)
Abbott
Phase 1 Completed
NCT00754104 2011-01-19
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
Abbott
Phase 1 Withdrawn